Roivant Q4 swings to profit of $355.7 million; revenue falls to $2.52 million

Roivant Sciences

Roivant Sciences

ROIV

0.00
  • Roivant posted net income attributable to shareholders of USD 302.99 million for the fourth quarter, swinging from a loss a year earlier.
  • Operating income turned positive at USD 415.24 million as the quarter included a USD 770.24 million litigation settlement gain tied to the Moderna agreement.
  • Revenue fell 66.71% to USD 2.52 million, while R&D expense climbed 36.98% to USD 198.95 million.
  • Cash, cash equivalents and marketable securities totaled USD 4.3 billion at March 31, 2026; the company said this supports runway into profitability.
  • Roivant reiterated a late-September 2026 expected launch for brepocitinib in dermatomyositis, with topline Phase 3 data in non-infectious uveitis and Phase 2 mosliciguat data in PH-ILD expected in the second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200700PRIMZONEFULLFEED9723696) on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.